Clinical outcomes in ROS1-fusion positive (ROS1+) non-small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were identified in 27 cases, including CD74 (n = 10), EZR (n = 7), and SDC4 …

Lignocellulose biorefining is a promising technologyfor the sustainable production of chemicals and biopolymers.Usually, when one component is focused on, the chemical natureand yield of the others are compromised. Thus, one of thebottlenecks in biomass biorefining is harnessing the maximumvalue from …

In dit onderzoek is er gekeken naar pleuravocht van een patiënt en de daarin aanwezige celtypes. Pleuravocht is een ophoping van vocht in de pleurale holtes tussen de borstkas en longen. Een vermeerdering van pleuravocht kan verschillende oorzaken hebben, zoals ontstekingen en tumoren. Om erachter te …

Protein kinases function as pivotal regulators in biological events, governing essential cellular processes through the transfer of phosphate groups from ATP molecules to substrates. Dysregulation of kinase activity is frequently associated with cancer, ocasionally arising from chromosomal translocation …

This research investigates growth inhibitors for smart services driven by condition-based maintenance (CBM). Despite the fast rise of Industry 4.0 technologies, such as smart sensoring, internet of things, and machine learning (ML), smart services have failed to keep pace. Combined, these technologies …

Arrhythmogenic Cardiomyopathy (ACM), also known as arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a rare hereditary disease of the heart, where the connective, and fatty tissue is deposited in the muscle tissue of the ventricular myocardium primarily of the right but also left …

Background The ROS1 G2032R mutation is the most common on-target resistance mutation in crizotinib treated ROS1-positive lung cancer patients. The aim of our study was to investigate resistance mechanisms in SCL34A2-ROS1G2032R positive Ba/F3 cells against second line treatment with lorlatinib. Methods …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, including canagliflozin, reduce the risk of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit with a large interindividual variation. The underlying mechanisms for this variation in response might be attributed …